^
Association details:
| Biomarker: | AR amplification |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Nubeqa (darolutamide) (Androgen receptor inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer: Experience from a safety-net hospital serving a racially and ethnically diverse patient population.
Published date:
02/13/2023
Excerpt:
We assessed the real-world effectiveness of darolutamide in a racially/ethnically diverse population of M1-CRPC....AR mutations that emerged or increased in ctDNA allele fraction while on darolutamide included L702H, H875Y, H100Q, D891H, T878A, L329W and AR copy number gain, suggesting a possible role in darolutamide resistance….However, prior resistance to enzalutamide/apalutamide and/or associated AR mutations can significantly decrease the likelihood of benefit from darolutamide.
DOI:
10.1200/JCO.2023.41.6_suppl.150
